Clearside Biomedical Announces Third Quarter 2024 …

News | Investor Relations | Clearside Biomedical, Inc.- IR SiteQuarterly Summary | Clearside Biomedical, Inc.- IR Site

21%
OFF

Clearside Biomedical Third Quarter 2024 Earnings: Beats …

1 week from now

1 day ago · Clearside Biomedical (NASDAQ:CLSD) Third Quarter 2024 Results Key Financial Results Revenue: US$1.04m (up 21% from 3Q 2023). Net loss: US$7.69m (loss narrowed by …

yahoo.com

$0.10
OFF

Clearside Biomedical (NASDAQ:CLSD) Raised To Hold At

1 week from now

1 day ago · Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.10) earnings per share (EPS) …

marketbeat.com

$7
OFF

VM | Visionmonday.com

1 week from now

4 days ago · Eyenovia Reports Net Loss of $7.9 Million in Third Quarter, Evaluates Long-Term Financing Options NEW YORK—Eyenovia, Inc. yesterday announced financial and operating …

visionmonday.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating …

1 week from now

3 days ago · Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September 30, 2024, compared with a net loss of …

morningstar.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating

1 week from now

2 days ago · Third quarter 2024 Financial Results . Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September …

biospace.com

$2417304
OFF

The Healthcare Foundation Of NJ Announces $2,417,304 In Third …

1 week from now

Sep 18, 2024 · The Healthcare Foundation of NJ (HFNJ) is pleased to announce that it has awarded $2,417,304 to eighteen nonprofit organizations in its third quarterly grant cycle of …

hfnj.org

FAQs about Clearside Biomedical Announces Third Quarter 2024 … Coupon?

What did Clearside biomedical do in the third quarter 2024?

ALPHARETTA, Ga., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ®), today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. ...

Is Clearside Biomedical Inc (CLSD) poised for growth?

With sufficient resources projected to fund operations into the third quarter of 2025, Clearside is poised for continued development and potential market expansion. Clearside Biomedical Inc ( (CLSD) ) has released its Q3 earnings. ...

Who is Clearside biomedical?

About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ®) to improve patient outcomes. ...

When will Clearside engage with the FDA?

The company plans to engage with the FDA in early 2025 to align on pivotal aspects of the next phase. With sufficient resources projected to fund operations into the third quarter of 2025, Clearside is poised for continued development and potential market expansion. ...

Does Clearside biomedical offer axitinib injectable suspension?

Clearside Biomedical announces plans for a Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in Wet AMD. Clearside Biomedical will participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference. ...

What time does Clearside hold a conference call?

Conference Call & Webcast Details Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. ...